This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Vertex Pharmaceuticals’ RAINIER's Phase 3 Trial Results of Povetacicept in IgA Nephropathy & Primary Membranous Nephropathy
Ticker(s): VRTX, CALT, TVTX, NVS, OTSKYWho's the expert?
Institution: University of Southern California
- Associate Professor of Medicine at Keck-USC School of Medicine & Medical Director of the CKD program and the Renal, Hypertension and Transplant Clinic at the LAC+USC.
- Treats 190 patients with IgA nephropathy or primary membranous nephropathy and patients with both HRS1 and HRS2 and over 200 patients with Anemia-CKD.
- Research focuses on advancing kidney dialysis, liver dialysis and providing a support system for the MOF/MODS multisystem failures; has been actively conducting major pharmaceutical sponsored phase II-IV clinical trials in hypertension, anemia, iron, and secondary hyperparathyroidism.
Interview GoalTo gain a deeper understanding of Vertex Pharmaceuticals’ Povetacicept as a potential treatment in IgA Nephropathy & Primary Membranous Nephropathy. Examining how it compares to
Tarpeyo, Filspari, Fabhalta, Vanrafia and Voyxact
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
